Chondrosarcoma market players and analysis by types, by diagnosis, by treatment, by end user - forecast till 2030
There has been a substantial rise in the incidence of chondrosarcoma over the years, and the global chondrosarcoma market is projected to grow at a CAGR of 6.8% by the end of 2030. The market has been growing persistently on account of the widespread prevalence of chondrosarcoma on a global scale which induces demand for diagnosis and treatment. Chondrosarcoma is a rare type of bone cancer that is most common in people older than 40 years, thus, a rise in global geriatric population boosts the growth of the market. Various governments across the globe have endeavored to provide treatment for the disease and contributing towards the development of therapies and medicines.
Additionally, a number of pharmaceutical and biotechnology firms are spending money on RD as well as clinical trials to find a cure for chondrosarcoma, a major market driver. The FDA's approval of numerous drugs has also contributed to the expansion of the market. The market's expansion is also supported by improvements in surgical techniques that enable less intrusive operations that result in less painful, more effective, and economical patient care. But no efficient treatment for it has yet been created. Additionally, chondrosarcoma is resistant to radiation and chemotherapy, which poses a significant barrier to the market's expansion.
Competitive Landscape
The global chondrosarcoma market players include Abbott. (US), Akorn, Inc. (US), Baxter (US), Epizyme, Inc. (US), Mylan N.V. (US), AbbVie Inc. (US), Agios, Inc. (US), Bayer AG (US), and Novartis AG (Switzerland).
SegmentationThe global chondrosarcoma market has been segmented based on type, diagnosis, treatment, and end user.
By type, the market has been segmented into conventional chondrosarcoma, clear cell chondrosarcoma, myxoid chondrosarcoma, mesenchymal chondrosarcoma, de-differentiated chondrosarcoma.
By diagnosis, the market has been segmented into biopsy, imaging, and others. Biopsy is further sub-segmented into shave open biopsy, core needle biopsy, and others. The imaging segment has been further segmented into X-Ray, Computed Tomography Scan (CT scan), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) Scan, and others.
By treatment, the market has been segmented into intensive surgery, therapies, hemipelvectomy, and others. The therapies segment has been further segmented into physical therapy, radiation therapy, chemotherapy, and others. The hemipelvectomy segment has been further segmented into external hemipelvectomy, internal hemipelvectomy, and others.
By end-user, the market has been segmented into hospitals and clinics, medical research centers, academic institutes, and others.
Regional Analysis
The global chondrosarcoma market spans across the regions of North America, Europe, Asia Pacific, and the Middle East Africa. North America accounts for the largest share of the market owing to the high prevalence of chondrosarcoma in the region coupled with a substantial investment in RD activities. Due to the existence of cutting-edge healthcare facilities in the region, particularly in Germany and the UK, Europe is the second-largest market. Chondrosarcoma incidence is on the rise in the Asia Pacific region, and the region's healthcare system is also getting better. Due to low disease awareness and an underdeveloped healthcare system in the region, the Middle East Africa market is anticipated to grow slowly over the forecast period.
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
Contact Us:
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5Th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)
Email: [email protected]
Website: https://www.marketresearchfuture.com
